Simard et al. found a sulfonylurea receptor 1 (SUR1)-regulated NCCa-ATP channel was involved in the development of brain oedema in rodent stroke models.6 Moreover, glibenclamide (an SUR1 inhibitor) has been shown to reduce the volume of infarction and swelling in rodent stroke models.7 There is a phase II clinical trial which showed intravenous glibenclamide reduced midline shift, and reduced death from brain oedema in patients with large hemispheric infarction (NCT01794182). Here, ABCC8 is linked to stroke disorder.